Acute left ventricular dysfunction following gemtuzumab ozogamicin in
two children with AML
Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-tumor antibiotic
conjugate with proven efficacy in pediatric and adult patients with
CD33+ acute myeloid leukemia (AML). Adverse effects commonly associated
with GO include hyperbilirubinemia, elevated transaminases, and
sinusoidal obstruction syndrome (SOS). Cardiotoxicity has not been a
commonly described adverse event. We describe two pediatric patients
with relapsed/refractory AML who received fractionated GO monotherapy
and subsequently developed severe acute left ventricular dysfunction.
Both patients achieved remission, recovered cardiac function with
medical therapy, and tolerated subsequent stem cell transplantation.